{"commentary":{"count":91,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":38,"podcast":25,"x_thread":24,"x_video":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05409066\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"EPCORE FL-1","nct_id":"NCT05409066","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=epcore-fl-1-nct05409066. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"EPCORE FL-1","arms":[{"description":"Participants will receive epcoritamab Dose A in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).","label":"Epcoritamab Dose A in Combination With R2","type":"EXPERIMENTAL"},{"description":"Participants will receive epcoritamab Dose B in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days). Enrollment is closed for this arm.","label":"Epcoritamab Dose B in Combination With R2","type":"EXPERIMENTAL"},{"description":"Participants will receive lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).","label":"Lenalidomide and Rituximab (R2)","type":"ACTIVE_COMPARATOR"}],"collaborators":["AbbVie"],"completion_date":{"date":"2029-12","type":"ESTIMATED"},"conditions":["Follicular Lymphoma (FL)"],"enrollment":{"count":549,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Epcoritamab","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"}],"last_update":"2026-07-08","lead_sponsor":"Genmab","official_title":"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of Participants Achieving Best Overall Response (BOR)","timeFrame":"Up to approximately 2 years and 3 months"},{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to approximately 2 years and 3 months"}],"references":[{"citation":"Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jimenez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F; EPCORE FL-1 Investigators. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet. 2026 Jan 10;407(10524):161-173. doi: 10.1016/S0140-6736(25)02360-8. Epub 2025 Dec 7.","pmid":"41371238","type":"DERIVED"}],"start_date":{"date":"2022-09-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma","url":"https://clinicaltrials.gov/study/NCT05409066"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/epcore-fl-1-nct05409066"}